Last reviewed · How we verify
NCT03711227
Procalcitonin at Zero and 24 Hours as a Prognostic Factor in Patients With Pneumonia
trial testing Procalcitonin lab test in Pneumonia in 185 participants. Completed in 1 August 2019.
1 August 2019
Quick facts
| Lead sponsor | Corewell Health South |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 185 |
| Start date | 17 July 2018 |
| Primary completion | 1 August 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Procalcitonin lab test
Conditions studied
- Pneumonia — all drugs for Pneumonia →
Sponsor
Corewell Health South — full company profile →
Who can join
18 and older, any sex, with Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Procalcitonin levels checked initially and at 24 hours will correlate with disease severity, morbidity, and mortality. Patients who have a higher procalcitonin level initially and at 24 hours will likely have higher qSOFA scores, longer lengths of stay, longer duration of antibiotics and higher 30 day mortality rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03711227
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pneumonia
Currently open trials in the same condition.
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07251465 — A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia · active not recruiting
- NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT06911658 — Infectious Complications After Esophagectomy · recruiting
Other Corewell Health South trials
Trials by the same sponsor.
- NCT06955013 — Ultrasound to View Abdominal Wall Muscle Layers · recruiting
- NCT06570395 — Osteopathic Manipulative Treatment in the Third Trimester of Pregnancy · terminated
- NCT06155643 — EKO SENSORA: Detecting Clinically Significant Murmurs · NA · recruiting
- NCT05367336 — Platelet Reactivity With Fentanyl, Morphine, or no Narcotic · Phase 2 · terminated
- NCT05473897 — Cooling Helmets to Decrease Concussion Symptoms · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03711227 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corewell Health South
- Last refreshed: 29 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03711227.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing